Cargando…

Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis

BACKGROUND: The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive extensive-stage SCLC patients, the efficacy of immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Bi-Cheng, Xiao, Bo-Ya, Li, Peng-Cheng, Kuang, Bo-Hua, Chen, Wang-Bing, Li, Pin-Dong, Lin, Guo-He, Liu, Quentin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542505/ https://www.ncbi.nlm.nih.gov/pubmed/33061969 http://dx.doi.org/10.1155/2020/2368164

Ejemplares similares

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
por: Zhang, Tianming, et al.
Publicado: (2023)

Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: Zhang, Shuang, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
por: Xie, Zhaoliang, et al.
Publicado: (2023)

Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis
por: Zhang, Shuang, et al.
Publicado: (2020)

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
por: Liang, Xueyan, et al.
Publicado: (2023)

Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study
por: Qu, Jingjing, et al.
Publicado: (2022)

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

IMpower, CASPIAN, and more: exploring the optimal first-line immunotherapy for extensive-stage small cell lung cancer
por: Huang, Chengliang, et al.
Publicado: (2020)

Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review
por: Wang, Tao, et al.
Publicado: (2023)

Consolidative Thoracic Radiation Therapy After First-Line Chemotherapy and Immunotherapy in Extensive-Stage Small Cell Lung Cancer: A Multi-Institutional Case Series
por: Diamond, Brett H., et al.
Publicado: (2021)

Efficacy of First-Line Immunotherapy Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients With Different Brain Metastases Status: A Systematic Review and Meta-Analysis
por: Zhao, Wen Hua, et al.
Publicado: (2023)

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer
por: Luo, Hao, et al.
Publicado: (2019)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer
por: Liu, Qiao, et al.
Publicado: (2021)

The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2020)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
por: Zhou, Fei, et al.
Publicado: (2020)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Effect of depression disorder on the efficacy and quality of life of first-line chemotherapy combined with immunotherapy in oncogene-driver negative NSCLC patients
por: Li, Wen, et al.
Publicado: (2022)

A Bayesian network analysis of immunotherapy and taxane chemotherapy as second- or later-line treatments in non-small cell lung cancer
por: Liu, Xin-Xiu, et al.
Publicado: (2022)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

Safety and Clinical Response to Combined Immunotherapy with Autologous iNKT Cells and PD-1(+)CD8(+) T Cells in Patients Failing First-line Chemotherapy in Stage IV Pancreatic Cancer
por: Wang, Jing, et al.
Publicado: (2023)

First-Line Chemo-Immunotherapy for Extensive-Stage Small-Cell Lung Cancer: A United States-Based Cost-Effectiveness Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis
por: Sathiyapalan, Arani, et al.
Publicado: (2022)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis
por: Chen, Hao, et al.
Publicado: (2020)

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

First-line immune-checkpoint inhibitor plus chemotherapy versus chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis
por: Landre, Thierry, et al.
Publicado: (2020)

Meta‐analysis of PD‐(L)1 inhibitor plus chemotherapy versus chemotherapy as first‐line treatment in extensive‐stage small‐cell lung cancer
por: Lu, Jiangyue, et al.
Publicado: (2023)

First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2021)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy
por: Shang, Bingqing, et al.
Publicado: (2022)

Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer
por: Li, Xin-Ru, et al.
Publicado: (2022)

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients
por: Wang, Min, et al.
Publicado: (2022)

The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study
por: Zheng, Hao-Ran, et al.
Publicado: (2022)

First-line Immuno-chemotherapy for extensive-stage small-cell lung cancer: A network meta-analysis and cost-effectiveness analysis
por: Zhu, Youwen, et al.
Publicado: (2023)

Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis
por: Cai, Zijing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ksdkoh8aiesup24j6d10slveh1